Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CODX
$2.334
$
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Next Earnings
2026-02-25
Beta
1.324
Average Volume
Market Cap
Last Dividend
CIK
0001692415
ISIN
US1897632048
CUSIP
189763105
CEO
Dwight H. Egan
Sector
Healthcare
Industry
Medical - Devices
Full Time Employees
132
IPO Date
2017-07-12
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Establishment Labs (NASDAQ:ESTA) vs. Co-Diagnostics (NASDAQ:CODX) Head to Head Contrast | Co-Diagnostics (NASDAQ: CODX - Get Free Report) and Establishment Labs (NASDAQ: ESTA - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Analyst Recommendations This is a summary of current ratings | Defense World | 2026-02-19 03:29:07 |
| Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai | SALT LAKE CITY, Feb. 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in an exhibition at the upcoming World Health Expo Labs Dubai ("WHX Labs"), taking place February 10–13, 2026, at the Dubai World Trade Centre. World Health Expo Labs Dubai, formerly Medlab Middle East, is a multi-day international exhibition that convenes laboratory professionals, healthcare leaders, diagnostics developers, and technology providers from around the world to address advancements and emerging needs in medical laboratory science. | PRNewsWire | 2026-02-09 09:00:00 |
| Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument | CDSCO license on Form MD-5 authorizes CoSara to manufacture PCR Pro instrument in its Ranoli, India facility for sale or distribution SALT LAKE CITY, Feb. 5, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has received a license from the Central Drugs Standard Control Organization ("CDSCO") to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument for sale or distribution. | PRNewsWire | 2026-02-05 09:00:00 |
| Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform | Company and CoSara believe that ISO certification is a critical component of the regulatory requirements for clearance of new platform SALT LAKE CITY, Feb. 4, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has successfully completed the necessary audits of its quality management system ("QMS") and that its manufacturing facility located in Vadodara, India, has been granted ISO 13485:2016 certification. | PRNewsWire | 2026-02-04 09:00:00 |
| Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships | SALT LAKE CITY, Jan. 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has been strengthening its distributor base across India, recently attending and participating in two regional conferences. | PRNewsWire | 2026-01-12 09:00:00 |
| CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform | CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance. | Zacks Investment Research | 2025-12-31 11:50:17 |
| Co-Diagnostics Announces Reverse Stock Split | SALT LAKE CITY, Dec. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-30 shares. The reverse stock split will become effective at 12:01 a.m. | PRNewsWire | 2025-12-30 09:00:00 |
| Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies | The Australian patent represents the first patent granted for the Company's new point-of-care testing platform SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Australian Patent Office has granted Australian Patent No. AU2022270084A1, strengthening Co-Dx's intellectual property portfolio surrounding its novel Co-Dx PCR platform*. | PRNewsWire | 2025-12-29 09:00:00 |
| Short Interest in Co-Diagnostics, Inc. (NASDAQ:CODX) Drops By 43.3% | Co-Diagnostics, Inc. (NASDAQ: CODX - Get Free Report) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totaling 646,208 shares, a decline of 43.3% from the November 30th total of 1,138,960 shares. Based on an average daily trading volume, of 1,424,156 shares, | Defense World | 2025-12-27 04:20:52 |
| Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India | SALT LAKE CITY , Dec. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its joint venture, CoSara Diagnostics Pvt. Ltd. ("CoSara"), has been invited to participate in the 2nd Advanced TB Diagnostics Course, a capacity-building workshop for countries in the South-East Asian Region (SEAR). | PRNewsWire | 2025-12-18 09:00:00 |
| Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation | SALT LAKE CITY , Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has performed an in silico analysis of the Co-Primers® used in its Logix Smart® ABC test* for the detection of influenza A, influenza B and COVID-19. The analysis showed a high homology against 3,900 influenza sequences, confirming comparable reactivity of the primer sets against the influenza A H3N2 subclade K. | PRNewsWire | 2025-12-17 09:00:00 |
| CarePayment Technologies (OTCMKTS:CPYT) & Co-Diagnostics (NASDAQ:CODX) Head to Head Survey | CarePayment Technologies (OTCMKTS:CPYT - Get Free Report) and Co-Diagnostics (NASDAQ: CODX - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations. Valuation and Earnings This table compares CarePayment Technologies and | Defense World | 2025-12-16 03:54:52 |
| Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025 | SALT LAKE CITY , Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company is delivering a presentation at the Point-of-Care Testing 2025 Exhibition and Conference in Boston, MA. The presentation, titled "Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics," will unpack Co-Dx's move to portable PCR diagnostics to address evolving point-of-care needs, introduce the Company's upcoming Co-Dx PCR platform* and intuitive smartphone interface, and discuss how Co-Dx is harnessing AI to minimize user error and improve outcomes in real-time point-of-care testing. | PRNewsWire | 2025-12-09 09:00:00 |
| Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India | Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing SALT LAKE CITY , Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture ("JV") between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will participate and host a booth at VIROCON 2025, taking place December 8-10 at the Conrad Hotel in Pune, Maharashtra, India. | PRNewsWire | 2025-12-08 12:36:00 |
| CoDiagnostics (CODX) Upgraded to Buy: Here's What You Should Know | CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | Zacks Investment Research | 2025-12-02 13:01:16 |
| Analysts Set Co-Diagnostics, Inc. (NASDAQ:CODX) PT at $1.83 | Shares of Co-Diagnostics, Inc. (NASDAQ: CODX - Get Free Report) have received a consensus recommendation of "Hold" from the five brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has | Defense World | 2025-11-29 01:12:51 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-11 | 2026-02-11 | View Filing |
| S-8 | 2026-01-21 | 2026-01-21 | View Filing |
| 8-K | 2026-01-13 | 2026-01-13 | View Filing |
| 8-K | 2025-12-30 | 2025-12-30 | View Filing |
| 424B5 | 2025-12-19 | 2025-12-19 | View Filing |
| 8-K | 2025-12-05 | 2025-12-05 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| SC 13G | 2025-11-13 | 2025-11-13 | View Filing |
| DEF 14A | 2025-11-10 | 2025-11-10 | View Filing |
| PRE 14A | 2025-10-31 | 2025-10-31 | View Filing |
| SC 13G/A | 2025-10-30 | 2025-10-30 | View Filing |
| SC 13G/A | 2025-10-30 | 2025-10-30 | View Filing |
| SC 13G/A | 2025-10-30 | 2025-10-30 | View Filing |
| 8-K | 2025-10-29 | 2025-10-29 | View Filing |
| 424B5 | 2025-10-28 | 2025-10-28 | View Filing |
| 8-K | 2025-09-30 | 2025-09-30 | View Filing |
| SC 13G/A | 2025-09-19 | 2025-09-19 | View Filing |
| SC 13G | 2025-09-18 | 2025-09-18 | View Filing |
| 8-K | 2025-09-18 | 2025-09-18 | View Filing |
| 424B5 | 2025-09-18 | 2025-09-18 | View Filing |
| 424B5 | 2025-09-16 | 2025-09-16 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-07-11 | 2025-07-11 | View Filing |
| 8-K | 2025-05-29 | 2025-05-29 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 10-Q | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-04-28 | 2025-04-28 | View Filing |
| DEF 14A | 2025-04-14 | 2025-04-14 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-02-21 | 2025-02-21 | View Filing |
| 8-K | 2025-01-10 | 2025-01-10 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 8-K/A | 2024-11-08 | 2024-11-08 | View Filing |
| 10-Q | 2024-11-07 | 2024-11-07 | View Filing |
| 8-K | 2024-11-07 | 2024-11-07 | View Filing |
| 424B5 | 2024-10-18 | 2024-10-18 | View Filing |
| 8-K | 2024-08-30 | 2024-08-30 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-08-08 | 2024-08-08 | View Filing |
| DEF 14A | 2024-07-16 | 2024-07-16 | View Filing |
| 8-K | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-05-28 | 2024-05-28 | View Filing |
| 4 | 2024-05-28 | 2024-05-28 | View Filing |
| 4 | 2024-05-28 | 2024-05-28 | View Filing |
| 4 | 2024-05-28 | 2024-05-28 | View Filing |
| 4 | 2024-05-28 | 2024-05-28 | View Filing |
| 4 | 2024-05-28 | 2024-05-28 | View Filing |
| 10-Q | 2024-05-09 | 2024-05-09 | View Filing |
| 8-K | 2024-05-09 | 2024-05-09 | View Filing |
| 4 | 2024-04-29 | 2024-04-29 | View Filing |
| 4 | 2024-04-29 | 2024-04-29 | View Filing |
| 4 | 2024-04-29 | 2024-04-29 | View Filing |
| 4 | 2024-04-29 | 2024-04-29 | View Filing |
| 4 | 2024-04-29 | 2024-04-29 | View Filing |
| 4 | 2024-04-29 | 2024-04-29 | View Filing |
| 4 | 2024-04-29 | 2024-04-29 | View Filing |
| 3 | 2024-03-20 | 2024-03-20 | View Filing |
| 8-K | 2024-03-15 | 2024-03-15 | View Filing |
| 10-K | 2024-03-14 | 2024-03-14 | View Filing |
| 8-K | 2024-03-14 | 2024-03-14 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Larry Williams PercentR Strategy | 166.96% | 1.01 | 196 | 0.03 | 0.18 | 166.9 |
| Fractal Pattern | 118.39% | 1.02 | 93 | 0.03 | 0.16 | 118.33 |
| Fibonacci | 103.61% | 0.99 | 636 | 0.02 | 0.06 | 103.56 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxx | xxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxx% | xxxx | xxx | x | xxxx | x |
| xxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |